Point Roberts WA, New York, NY - June 25, 2013 (Investorideas.com newswire) - Investorideas.com, an
investor
research portal specializing in investing ideas in leading sectors
including biotech and medical technology stocks, issues a trading alert
for
Aethlon Medical, Inc. (
OTCQB: AEMD), trading at $0.1199 0.0189 or 18.71% as of 11:00AM EDT on over 796,000 shares following FDA news.
The company reported today that the United States Food and Drug
Administration (FDA) has approved an Investigational Device Exemption
(IDE) that allows the Company to initiate human feasibility studies of
the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a
first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from
circulation.
Under the feasibility study protocol, Aethlon will enroll ten end
stage renal disease (ESRD) patients who are infected with the Hepatitis C
virus (HCV) to demonstrate the
safety
of Hemopurifier therapy. Successful completion of the feasibility study
will set the stage for Aethlon to conduct pivotal studies required for
market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates
innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology platform that provides the basis
for a new class of devices the rapid, yet selective removal of disease
promoting particles from the entire circulatory system. At present, The
Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to
address infectious disease and cancer, and a medical device being
developed under a 5-year contract with DARPA to reduce the incidence of
sepsis in combat-injured soldiers. For more information, please visit
www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector,
featuring stock news, commentary and trading alerts in leading sectors
including biotech, tech, mining, energy, water,
renewable energy
, beverage stocks and more.
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at
http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a
third party publisher of news and research Our sites do not make
recommendations, but offer information portals to research news,
articles, stock lists and recent research. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or
securities. This site is currently compensated by featured companies,
news submissions and
online
advertising. Disclosure: Investorideas has been compensated by AEMD for
news distribution and content publishing: three thousand per month
effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar
800-665-0411 or 212-822-8842
Source
www.Investorideas.com
No comments:
Post a Comment